|Bid||7.35 x 1300|
|Ask||9.50 x 900|
|Day's Range||7.46 - 7.87|
|52 Week Range||4.50 - 9.95|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2017 - Aug 18, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.71|
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
Corbus Pharmaceuticals (CRBP) needs investors to pay close attention to the stock based on moves in the options market lately.
Collaboration in-line with Corbus vision to become the global leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemAdvances.
NEW YORK, Dec. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical.
HENDERSON, NV / ACCESSWIRE / December 4, 2018 / The following stocks in the CBD/Biotech sectors look poised for big December's. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), CV Sciences, ...
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary in the Midtown area. The above chart lists the details about Curaleaf’s new dispensary in Tallahassee.
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf Holdings has announced that it will release its third-quarter earnings results on November 26. Analysts expect Curaleaf Holdings to report revenue of 31.4 million Canadian dollars in the third quarter.
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
22nd Century Group (XXII) is a plant biotechnology company that’s focused on developing technologies to manage the nicotine content in tobacco plants and the cannabinoids in cannabis plants using gene editing and plant breeding technologies.
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -23.81% and -34.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Norwood, Massachusetts-based company said it had a loss of 26 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Every investor in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders Read More...
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare.
- Company to host conference call and webcast on Nov. 8th at 8:30 AM ET - Norwood, MA, Nov. 05, 2018 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the.
Broadly the industry is divided into two markets: the market for medical marijuana and the one for recreational marijuana. According to a report released by research firm ArcView Market Research and BDS analytics, the overall share of the medical marijuana industry slid from 100% in 2013 to 71% in 2017. As of this writing, nine states have completely legalized recreational marijuana.) By 2027, medical marijuana will be just 33% of the overall market states ArcView.